RBC Capital Reiterates Outperform on Legend Biotech, Maintains $85 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on Legend Biotech (NASDAQ:LEGN) and maintained a price target of $85.
March 08, 2024 | 4:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating on Legend Biotech with a price target of $85.
The reiteration of an Outperform rating by a reputable analyst like Leonid Timashev from RBC Capital, along with maintaining a high price target of $85, suggests a strong bullish outlook for Legend Biotech. This endorsement is likely to instill confidence in investors and could lead to a positive short-term impact on the stock's price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100